Literature DB >> 12506771

Differentiating idiopathic inflammatory myopathies from metabolic myopathies.

Robert L Wortmann1, Salvatore DiMauro.   

Abstract

The metabolic myopathies are a heterogeneous group of diseases, including glycogenoses, disorders of lipid metabolism, and mitochondrial myopathies, that result primarily from inborn errors of metabolism. Most of these metabolic defects cause medical conditions that manifest early in life. Nevertheless, clinical presentations during the teenage years and adulthood are increasingly being recognized. Many of the clinical manifestations of these diseases are difficult to differentiate from those observed in the idiopathic inflammatory myopathies, especially polymyositis. A directed evaluation using the clinical, laboratory, and genetic approaches summarized in this article, however, should allow for the differentiation of most metabolic myopathies from polymyositis and other forms of idiopathic inflammatory myopathy. The diagnosis of a metabolic myopathy should be considered in patients who appear to have polymyositis but lack the characteristic changes of inflammation found on EMG, MRI, or muscle histology, or in such patients who are refractory to immunosuppressive therapy. The forearm ischemic exercise test is especially useful to screen for some inborn errors of glycogen metabolism or glycolysis and for myoadenylate deaminase deficiency. Thorough analysis of muscle tissue, including histology, histochemistry, biochemistry, and occasionally electron microscopy, is often necessary to make the diagnosis of a metabolic myopathy. Advances in molecular biology methods and knowledge of the precise genetic defects associated with these metabolic defects are dramatically increasing our capacity to diagnose patients with a widening range of myopathies. It is expected that, with further understanding of the mechanisms of the metabolic and idiopathic inflammatory myopathies, the differentiation of these disorders into their pathogenetic components, and the capacity to diagnose them will continue to improve. These are essential factors in improving genetic counseling and eventually the therapy of these serious, and currently incurable, disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12506771     DOI: 10.1016/s0889-857x(02)00022-4

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  3 in total

Review 1.  Differential diagnosis of idiopathic inflammatory myopathies.

Authors:  Alan N Baer
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

2.  Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease.

Authors:  B Sun; S Li; A Bird; D D Koeberl
Journal:  Gene Ther       Date:  2010-08-05       Impact factor: 5.250

3.  Muscle Weakness: A Misleading Presentation in Children With Distinctive Syndromic Entities (Clinical Case Reports).

Authors:  Ali Al Kaissi; Sergey Ryabykh; Polina Ochirova; Vladimir Kenis; Jochen G Hofstätter; Franz Grill; Rudolf Ganger; Susanne Gerit Kircher
Journal:  J Investig Med High Impact Case Rep       Date:  2017-01-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.